课题基金 / 基金详情

ROLE OF CD14 AND OTHER LPS RECEPTORS IN ENDOTOXIC SHOCK

ROLE OF CD14 AND OTHER LPS RECEPTORS IN ENDOTOXIC SHOCK
CD14 和其他 LPS 受体在内毒素休克中的作用
批准号:
6626337
负责人:
Sanna M Goyert
金额:
$39.4万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-01-01 至 2003-12-31

项目摘要

项目成果

Sanna M Goyert的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Verbatim from the applicant's abstract) The studies proposed will focus on further elucidating mechanisms through which CD14 influences the inflammatory response. Specific Aim 1: To define the relative role of the CD14:LPS interaction in the shock response to bacterial pathogens posessing various virulence fqactors. We have previously shown that CD14-deficient mice are highly resistant to the lethal effects of LPS and E. Coli 0111. Our hypothesis is that some Gram-negative bacteria will induce shock predominently via the CD14:LPS pathway while other bacteria having different virulance factors will induce shock via CD14 independent mechanisms. To test this hypothesis, we will first study the shock response of CD14-deficient and normal mice to a well characterized panel of E. coli expressing defined virulence determinants. Next, we will test the role of the CD14:LPS interaction in a peritonitis model of shock induced by cecal ligation and puncture. Finally, we will use an oral model of shock to examine the role of CD14 in the response to intracellular organisms that use unique mechanisms to evade the host immune defense. These studies will expand our understanding of the relative roleof the CD14:LPS interaction in shock induced by bacteria and will begin to elucidate the mechanisms operating in CD14:LPS mediated shock versus CD14-independent shock. Specific Aim 2: To define the relative role of the CD14:LPS interaction in local infection. We believe that the mechanisms operating systemic models will also operateon the local level. That is, those bacteria which cause inflammation in CD!14-deficient mice will cause a local inflammatory response in CD14-/- mice, similar to that of normal mice; those bacteria which do not cause shock in CD14-deficient mice will not cause tissue damage and will be quickly cleared. The results from these experiments should complement those in the shock model and lead to an enhanced understandingf of the mechanisms regulating virulence of these bacteria and their role im imflammation. Specific Aim 3: To determine the role of soluble CD14 (sCD14) in septic shock and local inflammation induced by LPS and various bacteria (Gram-negative, Gram-positive). Studies suggest that there are two pathways for activation with LPS; One that stimulates via membrane CD14 and one that stimulates via another pathway and requires a complex of performance sites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CHARACTERIZATION OF THE LPS RECEPTOR FOR ACUTE PHASE
  • 批准号:
    6386492
  • 项目类别:
  • 资助金额:
    $18.45万
  • 财政年份:
    2000
  • 负责人:
    Sanna M Goyert
  • 依托单位:
CHARACTERIZATION OF THE LPS RECEPTOR FOR ACUTE PHASE
  • 批准号:
    6194383
  • 项目类别:
  • 资助金额:
    $18.16万
  • 财政年份:
    2000
  • 负责人:
    Sanna M Goyert
  • 依托单位:
CHARACTERIZATION OF THE LPS RECEPTOR FOR ACUTE PHASE
  • 批准号:
    6520033
  • 项目类别:
  • 资助金额:
    $18.45万
  • 财政年份:
    2000
  • 负责人:
    Sanna M Goyert
  • 依托单位:
MOLECULAR ANALYSIS OF MACROPHAGE ACTIVATION VIA LBP--LPS
  • 批准号:
    2184577
  • 项目类别:
  • 资助金额:
    $11.21万
  • 财政年份:
    1992
  • 负责人:
    Sanna M Goyert
  • 依托单位:
国内基金
海外基金
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
  • 批准号:
    32302245
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    潘寒姁
  • 依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
  • 批准号:
    82371775
  • 项目类别:
    面上项目
  • 资助金额:
    46万元
  • 批准年份:
    2023
  • 负责人:
    朱慧媛
  • 依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
  • 批准号:
    31871817
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2018
  • 负责人:
    孙爱东
  • 依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
  • 批准号:
    81873549
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    刘玉兰
  • 依托单位: